Evaluation of the impact of a sequencing assay for detection of drug resistance on the clinical management of tuberculosis.
In 2012, the California Department of Public Health began using pyrosequencing (PSQ) to detect mutations associated with resistance to isoniazid, rifampin, quinolones and injectable drugs in Mycobacterium tuberculosis complex. We evaluated the impact of the PSQ assay on the clinical management of tuberculosis (TB) in California. TB surveillance and laboratory data for specimens submitted 8/1/2012-12/31/2016 were analyzed to determine time to effective treatment initiation. A survey of clinicians was used to assess how PSQ results influenced clinical decision-making. Of 1,957 specimens tested with PSQ, 52% were sediments and 46% were culture isolates, submitted 8 and 35 days (median) after collection, respectively. Among 36 patients with multidrug-resistant TB (MDR-TB) who had a sediment specimen submitted for PSQ, median time from specimen collection to MDR-TB treatment initiation was 12 days vs 51 days when PSQ was not used. Of 303 TB patients with a completed survey, 126 (42%) clinicians reported PSQ as a reason for treatment change. Twenty-one patients either had an MDR-TB risk factor and a smear positive sputum specimen, but had PSQ performed on a culture isolate (9 of 36; 25%); or, didn't have PSQ used for MDR-TB diagnosis (12 of 38; 32%) and thus, had an opportunity for earlier MDR-TB diagnosis with PSQ on sediment. Patients with MDR-TB initiated effective treatment five weeks earlier when PSQ was used compared to those without PSQ. Survey data suggest clinicians use PSQ to devise effective TB drug regimens. To maximize the benefit of PSQ, earlier submission of specimens should be prioritized.